p Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience

doi:10.2147/PPA.S346171

科研成果详情

题名	p Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience
作者	Xie, Qingqing1; Sun, Caixia2; Fei, Zhenghua1; Yang, Xujing1
发表日期	2022
发表期刊	PATIENT PREFERENCE AND ADHERENCE 影响因子和分区
语种	英语
原始文献类型	Article
关键词	anxiety depression cancer immunotherapy quality of life
其他关键词	HOSPITAL ANXIETY ; SCALE ; NIVOLUMAB ; ANTIBODY
摘要	Background: Tumor immunotherapy is a promising therapeutic strategy for patients with advanced cancers, and some tumors have profound and durable tumor regression. However, immunotherapy is still in the clinical trial stage with elusive long-term effects and complications as a new strategy. It is unclear whether patients possess an accurate understanding of the clinical benefits associated with these agents. Objective: To investigate the anxiety and depression of patients with advanced cancer who received immunotherapy using programmed death-1 or programmed death-ligand 1 after multiline treatment failure, explore the influencing factors, and provide a reference for clinical medical staff and psychological support for patients. Methods: The Hospital Anxiety and Depression Scale was used to calculate the anxiety and depression scores before and after 1, 2, and 3 courses of treatment, respectively. The patients with anxiety and depression were counted. Purposive sampling was used to conduct face-toface semi-structured interviews with 21 patients to find out the reasons. The obtained data were analyzed and collated using Colaizzi's phenomenological method. Results: One hundred and twenty-six patients with advanced cancers were included in the study. Before and after 1, 2 and 3 courses of treatment, 18.26%, 23.0%, 50% and 54% of patients suffered from anxiety and depression, respectively. The proportion of patients with anxiety and depression during immunotherapy kept increasing, mainly due to therapeutic efficacy below expectation, lack of timely information after treatment, lack of awareness of treatment and drugs, and lack of family and social support. Conclusion: Patients with advanced tumors after multiline treatment failure are susceptible to anxiety and depression during immunotherapy. It is necessary to test the emotional state of patients in time and carry out early intervention. Nursing staffs and medical staffs should adopt personalized measures to meet the psychological needs of patients.
出版者	DOVE MEDICAL PRESS LTD
出版地	ALBANY
ISSN	1177-889X
卷号	16 页码:1-9
DOI	10.2147/PPA.S346171
页数	9
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
WOS记录号	WOS:000741553100001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	35023904
PMC记录号	PMC8743985
SCOPUSEID	2-s2.0-85130211024
通讯作者地址	[Yang, Xujing]Department of Radiation and Medical Oncology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China
Scopus学科分类	Medicine (miscellaneous);Social Sciences (miscellaneous);Pharmacology, Toxicology and Pharmaceutics (miscellaneous);Health Policy
引用统计	被引频次[WOS]：0 [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/11660
专题	附属第一医院
通讯作者	Yang, Xujing
作者单位	1.Department of Radiation and Medical Oncology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China; 2.Department of Nursing,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Xie, Qingqing,Sun, Caixia,Fei, Zhenghua,et al. p Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience[J]. PATIENT PREFERENCE AND ADHERENCE,2022,16:1-9.
APA	Xie, Qingqing, Sun, Caixia, Fei, Zhenghua, & Yang, Xujing. (2022). p Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience. PATIENT PREFERENCE AND ADHERENCE, 16, 1-9.
MLA	Xie, Qingqing,et al."p Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience".PATIENT PREFERENCE AND ADHERENCE 16(2022):1-9.